NASDAQ:CRTX Cortexyme (CRTX) Stock Price, News & Analysis $1.72 -0.11 (-6.01%) As of 08/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesTrendsBuy This Stock About Cortexyme Stock (NASDAQ:CRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cortexyme alerts:Sign Up Key Stats Today's Range$1.72▼$1.8550-Day Range$1.05▼$1.9052-Week Range$1.78▼$40.66Volume256,720 shsAverage Volume620,672 shsMarket Capitalization$51.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Read More Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. Email Address CRTX Stock News HeadlinesCrism Thera Regulatory NewsAugust 4, 2024 | lse.co.ukCortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.comAugust 1, 2022 | marketscreener.comMGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly income to cover housing, healthcare, food, and fun... With a fraction of what you probably think you need.August 14 at 2:00 AM | Investors Alley (Ad)Cortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.comJuly 27, 2022 | marketscreener.comMCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business WireJuly 27, 2022 | businesswire.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business WireJuly 27, 2022 | businesswire.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.comJuly 27, 2022 | marketscreener.comMCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo FinanceJuly 27, 2022 | finance.yahoo.comSee More Headlines CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed this year? Cortexyme's stock was trading at $1.85 on January 1st, 2025. Since then, CRTX stock has decreased by 1.1% and is now trading at $1.83. How were Cortexyme's earnings last quarter? Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.05. When did Cortexyme IPO? Cortexyme (CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. How do I buy shares of Cortexyme? Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cortexyme own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T). Company Calendar Last Earnings8/09/2021Today8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryHealth Care Technology Current SymbolNASDAQ:CRTX CIK1145404 Webwww.cortexyme.com Phone(650) 910-5717FaxN/AEmployees55Year Founded2012Profitability EPS (Trailing Twelve Months)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.96% Return on Assets-63.53% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.46Miscellaneous Outstanding Shares30,151,000Free Float21,739,000Market Cap$55.18 million OptionableNot Optionable Beta1.40 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CRTX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTesla is in troubleThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.